King Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for KING PHARMS, and what generic alternatives to KING PHARMS drugs are available?
KING PHARMS has twenty-seven approved drugs.
There is one US patent protecting KING PHARMS drugs.
There are two patent family members on KING PHARMS drugs in two countries and nine supplementary protection certificates in six countries.
Drugs and US Patents for King Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
King Pharms | SYNERCID | dalfopristin; quinupristin | INJECTABLE;INTRAVENOUS | 050748-001 | Sep 21, 1999 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
King Pharms Llc | PENICILLIN G PROCAINE | penicillin g procaine | INJECTABLE;INJECTION | 060101-001 | Approved Prior to Jan 1, 1982 | RX | No | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
King Pharms Llc | INTAL | cromolyn sodium | AEROSOL, METERED;INHALATION | 018887-001 | Dec 5, 1985 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
King Pharms Llc | TAPAZOLE | methimazole | TABLET;ORAL | 040320-001 | Mar 31, 2000 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for King Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
King Pharms Llc | AVINZA | morphine sulfate | CAPSULE, EXTENDED RELEASE;ORAL | 021260-006 | Dec 18, 2008 | 6,066,339 | ⤷ Try a Trial |
King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-001 | May 25, 2001 | 6,555,581 | ⤷ Try a Trial |
King Pharms Llc | TILADE | nedocromil sodium | AEROSOL, METERED;INHALATION | 019660-001 | Dec 30, 1992 | 4,760,072 | ⤷ Try a Trial |
King Pharms | LEVOXYL | levothyroxine sodium | TABLET;ORAL | 021301-001 | May 25, 2001 | 7,067,148 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for KING PHARMS drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsules | 30 mg, 60 mg, 90 mg and 120 mg | ➤ Subscribe | 2007-06-04 |
➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2004-11-04 |
➤ Subscribe | Extended-release Capsules | 45 mg and 75 mg | ➤ Subscribe | 2009-07-30 |
International Patents for King Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Canada | 2626027 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2007094825 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for King Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1539166 | 92323 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
0350733 | SPC/GB03/034 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313 |
0265685 | 99C0001 | Belgium | ⤷ Try a Trial | PRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919 |
1539166 | SPC/GB13/070 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: THE COMBINATION OF: (A) DEXTROMETHORPHAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. DEXTROMETHORPHAN HYDROBROMIDE AND IN PARTICULAR DEXTROMETHORPHAN HYDROBROMIDE MONOHYDRATE; AND (B) QUINIDINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, E.G. Q; REGISTERED: UK EU/1/13/833 20130626 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.